预约演示
更新于：2025-06-06
Polaprezinc
聚普瑞锌
更新于：2025-06-06
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1994-10-06), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C9H12N4O3Zn |
InChIKeyBORYQUPWNLXKFE-FJXQXJEOSA-M |
CAS号107667-60-7 |
关联
48
项与 聚普瑞锌 相关的临床试验CTR20250777
聚普瑞锌口腔崩解片人体药代动力学对比研究
CTR20244758
聚普瑞锌颗粒健康人体生物等效性研究
CTR20243088
评估受试制剂聚普瑞锌颗粒与参比制剂聚普瑞锌颗粒（Promac®）作用于健康成年受试者在空腹/餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究。
100 项与 聚普瑞锌 相关的临床结果
登录后查看更多信息
100 项与 聚普瑞锌 相关的转化医学
登录后查看更多信息
100 项与 聚普瑞锌 相关的专利（医药）
登录后查看更多信息
402
项与 聚普瑞锌 相关的文献（医药）2025-06-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Development of mucoadhesive films with high polaprezinc content for oral mucositis: A study on formulation and near-infrared spectroscopy-based quality control
Article
作者: Tahara, Kohei ; Suzuki, Akio ; Funato, Miyui ; Yamazoe, Eriko ; Ito, Takuya ; Ito, Takaaki
Polaprezinc (PLZ) has drawn attention to its potential to prevent oral mucositis caused by chemotherapy and radiotherapy. PLZ-containing lozenges have been developed in previous reports; however, for patients with mucositis, taking them may be challenging because of pain. Therefore, this study aimed to develop a mucoadhesive film containing the same amount (18.75 mg) of PLZ as a lozenge as a new dosage form to replace lozenges and evaluate its characteristics. First, various films were created using solvent casting to screen polymers with high PLZ content. Thus, hydroxypropyl cellulose (HPC) was selected; however, film curvature and reduced flexibility necessitated formulation optimization. The optimized films exhibited excellent content uniformity, stability, and mucoadhesive properties, with no significant changes in the drug content after storage. Furthermore, the possibility of using portable near-infrared spectroscopy (Micro NIR™) for the quality control of PLZ films was investigated. Multivariate analysis revealed that the Micro NIR calibration model predicted drug concentrations comparable to those measured by high-performance liquid chromatography. These results suggest that a mucoadhesive film with high PLZ content has been developed and that efficient quality control is possible using Micro NIR™.
2025-05-17BIOLOGICAL & PHARMACEUTICAL BULLETIN
Treatment of Long Coronavirus Disease in Japan: A Nationwide Study of Symptom-Associated Drug Prescriptions
Article
作者: Ando, Wataru ; Sugawara, Mitsuhiro ; Kogure, Yuka ; Sakamaki, Kyoka
Long coronavirus disease (COVID) is characterized by symptoms persisting or reappearing at least 2 months post-recovery from acute coronavirus disease 2019 (COVID-19). Although Long COVID symptoms have been widely studied, data on drug prescriptions for patients with Long COVID in Japan remain limited. Therefore, this study aimed to analyze drug utilization patterns for Long COVID treatment using a nationwide database in Japan, with the goal of providing basic data to support the establishment of standard treatments in the future. The Medical Data Vision COVID-19 dataset was used to identify patients diagnosed with Long COVID between January 15, 2020 and December 31, 2022. Symptoms and prescribed medications were extracted, and descriptive statistics were used to analyze the relationship between symptoms and drug prescriptions. Among 652016 patients with COVID-19, 3769 (0.6%) developed Long COVID. Common symptoms included fatigue, bronchial asthma-like symptoms, and insomnia. Acetaminophen was the most prescribed drug in the first month of diagnosis. Other frequently prescribed drugs included dextromethorphan, l-carbocisteine, and polaprezinc. From 3 months post-diagnosis, prescriptions for Hochu-ekki-to (a traditional Japanese herbal medicine; Kampo medicine) and polaprezinc increased, especially among patients aged 30-50 years. Long COVID in Japan is characterized by a wide range of symptoms, leading to symptom-based drug prescriptions, particularly fatigue, respiratory issues, and taste disturbances. These findings offer insights into the pharmacological management of Long COVID in Japan, highlighting the need for further research on optimal treatments in the future.
2024-02-01Auris, nasus, larynx
Diagnosis and treatment of taste disorders in Japan
Review
作者: Tsuzuki, Kenzo ; Nin, Tomomi
Though 270,000 patients with complaints of taste abnormalities visited medical institutions annually in 2019 survey, there are no drugs for the treatment of taste disorders that are covered by health insurance in Japan. In the survey, the number of patients with taste disorders was correlated with age, and the need for medical treatment for taste disorders is expected to increase in the future because of the super-aging society. The pathophysiology of taste disorders varies widely. There is an obvious need to decide the site and the causes of the disorder and understand the mechanism, by performing various examinations. It needs to first adjust the causative systemic diseases and medications in the treatment for taste disorder. Damage of taste cells due to zinc deficiency is the main pathophysiological mechanism of taste disorders, and zinc supplementation is a standard treatment in Japan. Oral zinc therapy is the treatment for taste disorders due to zinc deficiency or idiopathic taste disorder; though a double-blind study was conducted, it was considered low-level evidence in a clinical review. In Japan, the off-label use of polaprezinc for taste disorders was approved in 2011, and zinc acetate hydrate was approved for hypozincemia in March 2017, making it easier to use oral zinc therapy in general. In some cases, psychotherapy or herbal medicine therapy has been used with remarkable success, although its effectiveness has not been clearly tested. It might be expected to offer some help to patients. In the treatment of elderly patients with taste disorders, physicians need to consider the difference between "age-related changes in taste in healthy people" and "taste disorders in elderly persons", and they should separate them. Aggressive treatment is desirable regardless of age, because no significant difference in the efficacy of various treatments was found between patients older and younger than 65 years.
100 项与 聚普瑞锌 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃溃疡 | 日本 | 1994-10-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Pubmed 人工标引  | N/A | 224 | 網憲獵範鑰遞網願襯選(製構遞築窪製齋願齋繭) = 艱醖鹹鹹醖願選網餘夢 遞築鑰繭鹽憲壓簾範鏇 (鹽鏇夢餘蓋廠鏇觸糧獵 ) 更多 | 不佳 | 2022-08-12 | ||
網憲獵範鑰遞網願襯選(製構遞築窪製齋願齋繭) = 鑰獵壓鹽獵顧餘遞夢衊 遞築鑰繭鹽憲壓簾範鏇 (鹽鏇夢餘蓋廠鏇觸糧獵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用